ArticleLaryngoscope investigative otolaryngology2026
Does PD-L1 Combined Positive Score Have Prognostic Value in Hypopharyngeal Squamous Cell Carcinoma? A Retrospective Cohort Study.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of this study was to determine whether pretreatment PD-L1 CPS is prognostically associated with survival in patients with HPSCC treated nonsurgically and without immunotherapy, and to assess overall survival (OS) in actively treated patients without distant metastases according to CPS < 1 versus CPS ≥ 1. Methods: This retrospective single-center study included 71 patients; the primary cohort comprised 56 M0 patients receiving active treatment. CPS was categorized as < 1 versus ≥ 1. Overall survival (OS) and progression-free survival (PFS), defined as progression or death, were analyzed using Kaplan-Meier and adjusted Cox models for age, ECOG performance status, grouped T stage, and nodal status. Sensitivity analyses examined broader cohorts and treatment covariates. Results: In the primary cohort, 47 deaths and 49 PFS events occurred. Median OS was 9 versus 18 months for CPS < 1 versus ≥ 1 ( Conclusions: CPS ≥ 1 was associated with longer OS and PFS in the primary cohort, with consistent OS estimates across sensitivity analyses. These hypothesis-generating findings require external validation and do not support CPS as a standalone treatment-selection marker. Level of Evidence: 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.